Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Agarwal, N., Mcquarrie, K., Bjartell, A., Chowdhury, S., Pereira De Santana Gomes, A.J., Chung, B.H., Özgüroğlu, M., Juárez Soto, Á., Merseburger, A.S., Uemura, H., Ye, D-W., Given, R., Miladinovic, BVolume:
18
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/s1569-9056(19)34587-7
Date:
November, 2019
File:
PDF, 144 KB
english, 2019
File converter
More search results
More benefits 
